



---

**Name:** COMPLETE / SUBSTANCE : 1-propene, tetramer / 6842-15-5 Fri, 16 Dec 2022, 16:16:07+0900 /

---

**Legal entity owner:** National Institute of Health Sciences

---

**Printing date:** 2022-12-16T16:16:08.007+09:00

---

## Table of Contents

0/0 .....	1
National Institute of Health Science .....	2
1-propene, tetramer .....	3
CORE .....	3
1 General information .....	3
1.10 Assessment approach (assessment entities) .....	3
Assessment approach (assessment entities) .....	3
OECD .....	4
D Health Effects .....	4
60 Acute toxicity: oral .....	4
Acute toxicity: oral.001 .....	4
67 Repeated dose toxicity: oral .....	8
Repeated dose toxicity: oral.001 .....	8
70 Genetic toxicity in vitro .....	16
Genetic toxicity in vitro.001 .....	16
Genetic toxicity in vitro.002 .....	20
73 Toxicity to reproduction .....	24
Reproductive/developmental toxicity.001 .....	24
DOMAIN .....	31
Substance .....	31
Substance .....	31
References .....	32
Reference Substances .....	32
1-propene, tetramer .....	32
Test Materials .....	33
1-Propene, tetramer .....	33
1-Propene, tetramer .....	34
1-Propene, tetramer .....	35
1-Propene, tetramer .....	36
Literatures .....	37
Combined repeat dose and reproductive/developmental toxicity screening test of 1-Propene, tetramer by oral administration in rats .....	37
In Vitro Chromosomal Aberration Test of 1-Propene, tetramer on Cultured Chinese Hamster Cells. ....	38
Reverse Mutation Test of 1-Propene, tetramer on Bacteria. ....	39
Single Dose Oral Toxicity Test of 1-Propene, tetramer in Rats .....	40
Legal Entities .....	41
National Institute of Health Sciences .....	41

---

# DOSSIER:

---

**UUID:** 0

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:16:07.825+09:00

**Remarks:**

---

## Dossier header

---

## Dossier submission type

---

**Name**

Complete table of contents

**Version**

core 7.0

**Name (given by user)**

## Dossier subject

---

**Dossier subject**

[1-propene, tetramer / 6842-15-5](#)

**Public name**

**Submitting legal entity**

[National Institute of Health Science](#)

**Dossier creation date/time**

Fri, 16 Dec 2022, 16:16:07+0900

**Used in category**

---

# LEGAL\_ENTITY: National Institute of Health Science

---

**UUID:** f51e7b54-9211-4863-90ce-fcf8a155d647

**Dossier UUID:**

**Author:**

**Date:** 2022-11-07T16:24:02.822+09:00

**Remarks:**

---

## General information

---

**Legal entity name**

National Institute of Health Science

---

# 1-propene, tetramer

## CORE

### General information

#### Assessment approach (assessment entities)

FIXED\_RECORD: Assessment approach

---

**UUID:** ce018663-1b31-3ddc-a47b-e717a1c48cd5

**Dossier UUID:**

**Author:**

**Date:** 2016-12-21T14:37:12.000+09:00

**Remarks:**

---

---

# OECD

## Health Effects

**Acute toxicity: oral**

ENDPOINT\_STUDY\_RECORD: Acute toxicity: oral.001

---

**UUID:** IUC5-42c5e945-ea8f-47a0-aa27-0890a1df8e11

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:12:07.019+09:00

**Remarks:**

---

## Administrative data

---

**Endpoint**

acute toxicity: oral

**Type of information**

experimental study

**Adequacy of study**

key study

**Robust study summary**

false

**Used for classification**

false

**Used for SDS**

false

**Reliability**

1 (reliable without restriction)

**Rationale for reliability incl. deficiencies**

other: OECD Test Guideline study under GLP condition

## Data source

---

**Reference**

[Single Dose Oral Toxicity Test of 1-Propene, tetramer in Rats / MHLW, Japan / study report](#)

**Data access**

data published

## Materials and methods

---

**Test guideline**

**Qualifier**

according to guideline

---

---

**Guideline**

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

**Test type**

acute toxic class method

**Limit test**

no

---

**Test material****Test material information**

1-Propene, tetramer

---

**Test animals****Species**

rat  
common species

**Strain**

other: CrI:CD(SD)

**Sex**

female

**Details on test animals or test system and environmental conditions****TEST ANIMALS**

- Source :Charles River Japan Inc.
- Age at study initiation: 9~10 weeks old
- Weight at study initiation: females, 236 (233-238) g (1st step group), 237 (234-242) g (2nd), 237 (232-241) g (3rd), 236 (233-240) g (4th)
- Fasting period before study: Approximately 16 hrs
- Housing: 3/cage
- Diet (e.g. ad libitum): Ad libitum except fasting period for 16 hrs before administration to 3 hrs after administration
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: 5 days

**ENVIRONMENTAL CONDITIONS**

- Temperature (°C): 22±3 °C(actual temperature: 21.2-22.1°C)
- Humidity (%): 55 ± 10% (actual humidity: 58-62%)
- Air changes (per hr): > 10 times/hr
- Photoperiod (hrs dark / hrs light): 12 hrs light / 12 hrs dark

---

**Administration / exposure****Route of administration**

oral: gavage

**Vehicle**

olive oil

**Details on oral exposure**

- Amount of vehicle (if gavage): 5 ml/kg bw

**Doses**

300 mg/kg bw (1st and 2nd steps), 2000 mg/kg bw (3rd and 4th steps)

---

**No. of animals per sex per dose**

3 (each step)

**Control animals**

no

**Details on study design**

- Duration of observation period following administration: 14 days
- Frequency of observations: nearly successive observation (from time just to 1 hr after administration ) and observation of every 2 hr (from 2 hr – 6 hr after administration) (day 0); twice a day (day 1); once a day (from day 2-day14)
- Frequency of weighing: just before administration (day 0), and 3,7 and 14 day after administration
- Necropsy of survivors performed: yes

---

**Results and discussion****Effect levels****Key result**

false

**Sex**

female

**Dose descriptor**

LD50

**Effect level**

ca. 5000

mg/kg bw

**Mortality**

No deaths were observed in any group.

**Clinical signs**

other: Diarrhea was observed at 300 mg/kg bw. Decreased locomotor activity, diarrhea and soiled perineal region were observed at 2000 mg/kg bw.

**Gross pathology**

No changes related to the test substance were observed in any group.

---

**Any other information on results incl. tables**

*Figures and Tables (in English) are available in the following full report of the study.*

*[http://dra4.nihs.go.jp/mhlw\\_data/home/pdf/PDF6842-15-5a.pdf](http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF6842-15-5a.pdf)*

---

**Applicant's summary and conclusion****Interpretation of results**

Category 5 based on GHS criteria Migrated information



---

**Conclusions**

No deaths were observed at 300 and 2000 mg/kg bw. The LD50 was considered to be approximately 5000 mg/kg bw (GHS: 5).

**Executive summary**

The acute oral LD50 of 1-propene, tetramer was > 2,000 mg/kg bw in female rats based on a study conducted according to OECD TG 423. No deaths were observed at 2,000 mg/kg bw. This substance at 300 mg/kg bw caused diarrhea and at 2,000 mg/kg bw caused decreased locomotor activity, diarrhea, and soiled perineal region.

---

## Repeated dose toxicity: oral

ENDPOINT\_STUDY\_RECORD: Repeated dose toxicity: oral.001

---

**UUID:** IUC5-8ed0c66e-401a-4010-aec3-de2e382eddd0

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:13:23.471+09:00

**Remarks:**

---

## Administrative data

---

### Endpoint

short-term repeated dose toxicity: oral combined repeated dose and reproduction / developmental screening

### Type of information

experimental study

### Adequacy of study

key study

### Robust study summary

false

### Used for classification

false

### Used for SDS

false

### Reliability

1 (reliable without restriction)

### Rationale for reliability incl. deficiencies

other: The study was conducted in accordance with Test Guidelines and under GLP.

### Cross-reference

#### Reason / purpose for cross-reference

reference to same study

#### Remarks

7.8.1 Reproductive/developmental toxicity.001

---

## Data source

---

### Reference

[Combined repeat dose and reproductive/developmental toxicity screening test of 1-Propene, tetramer b / MHLW, Japan / study report](#)

### Data access

data published

---

---

## Materials and methods

---

### Test guideline

**Qualifier**

equivalent or similar to guideline

**Guideline**

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

**GLP compliance**

yes

**Limit test**

no

---

## Test material

---

**Test material information**

[1-Propene, tetramer](#)

---

## Test animals

---

**Species**

rat

common rodent species

**Strain**

other: CrI: CD(SD)

**Sex**

male/female

**Details on test animals or test system and environmental conditions****TEST ANIMALS**

- Source: Charles River Laboratories Japan, Inc. Atsugi
- Age at study initiation: 8 weeks
- Weight at study initiation: Males: 264-308 g; Females: 178-225 g
- Housing: bracket-type metallic wire-mesh cages (W 260 × D 380 × H 180 mm)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 12 days

**ENVIRONMENTAL CONDITIONS**

- Temperature (°C): 20-24
- Humidity (%): 41-58
- Air changes: 10-15 times / hr
- Photoperiod: 12 hrs dark / 12 hrs light

---

## Administration / exposure

---

**Route of administration**

oral: gavage

---

**Vehicle**

corn oil

**Details on oral exposure**

PREPARATION OF DOSING SOLUTIONS: Test substance was dissolved in corn oil for injection.

**VEHICLE**

- Lot/batch no. (if required): VIR7200 produced by Nacalai Tesque, INC.
- Dosing volume: 5 mL/kg bw
- Stability (test solutions): At least 9 days
- Storage condition of test solution: Room temperature

**Analytical verification of doses or concentrations**

yes

**Details on analytical verification of doses or concentrations**

Test suspensions at each concentration to be used for males in week 1 and six week of administration were analyzed by the HPLC method at Nisso chemical analysis service Co., Ltd. Results showed that the concentration of the test article in each suspension was 99.7 to 108.2% of the nominal concentration and both values were within the acceptable range (concentration: percentage of the nominal concentration,  $100 \pm 10\%$ ; C.V.: 10% or below)

**Duration of treatment / exposure**

(P) Males: 42 days including 14 days pre-mating, mating, and thereafter 14 days

(P) Females: 42–51 days including 14 days pre-mating, mating and gestation periods and the days until day 4 of lactation. 42 days for satellite females (without mating).

**Frequency of treatment**

Once/day, 7 days/week

**Doses / concentrations****Remarks**

Doses / Concentrations:

0 (vehicle), 40, 150, and 600 mg/kg bw/day

Basis:

actual ingested

**No. of animals per sex per dose**

12 animals/sex/dose as a main dose group,

5\* males and 5 females at 0 and 600 mg/kg bw/day as a satellite group (without mating)

\* From corresponding main dose groups

**Control animals**

yes, concurrent vehicle

**Details on study design**

- Dose selection rationale: Doses in this test were set based on the results of the following dose-setting study: a 14-day repeated dose oral toxicity test (doses: 0, 30, 100, 300, and 1000 mg/kg bw/day). In the dose-setting study, increased liver and kidney weights were observed at 300 mg/kg bw/day and above, and diarrhea, mucous stool, low values of body weight and food consumption, high values of urine volume, ALT, urea nitrogen, creatinine and total cholesterol were observed at 1000 mg/kg bw/day. On the basis of these effects, a dose level of 600 mg/kg was selected as the maximum dose expecting to induce the toxic changes, and then dose levels of 150 and 40 mg/kg bw/day were selected as a middle dose and a minimum dose levels, respectively, in accordance with a common ratio of approximately 4.

- Rationale for animal assignment (if not random): Body weight-balanced randomization

---

- Post-exposure recovery period in satellite groups: 14 days

## Examinations

---

### Observations and examinations performed and frequency

CAGE SIDE OBSERVATIONS: Yes

- Time schedule:

Males and females: 2 times/day during the administration period (before and after dosing) and the recovery period (am and pm)

DETAILED CLINICAL OBSERVATIONS: Yes

The functional observational battery testing (FOB) was performed on all animals. Among the measures in the FOB, detailed clinical observations were made before the initiation of dosing. Thereafter, in males of the main groups, detailed clinical observations were made once a week. Also in females of the main groups, detailed clinical observations were made once a week in pre-mating and mating periods thereafter, and then those were made on days 1, 7, 14 and 20 of gestation, and on day 4 of lactation. For the satellite group, detailed clinical observations were made once a week in dosing and recovery periods.

Sensory motor reflexes, forelimb and hindlimb grip strengths, and motor activity were measured on week 6 of administration period (main/recovery group animals) and week 2 of recovery period (recovery group animals).

BODY WEIGHT: Yes

- Time schedule for examinations: Males (main/recovery group): Days 1, 3, 5, 7, 10, 14, 21, 28, 35, 42, and the day of necropsy (after ca. 16h-fasting) in dosing period

Males and females (recovery group): Days 1, 7, 14, and the day of necropsy (after ca. 16h-fasting) in recovery period

Females (main group): Twice a week during the precopulation period (days 1, 3, 5, 7, 10, and 14); gestation days 0, 1, 3, 5, 7, 10, 14, 17, and 20; lactation days 0, 1, and 4; and the day of necropsy (after ca. 16 h-fasting)

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):

- Food consumption: Yes, same days of the measuring of body weight

OPHTHALMOSCOPIC EXAMINATION: No

HAEMATOLOGY: Yes

- Time schedule for collection of blood: Blood was collected on the day of necropsy

- Anaesthetic used for blood collection: Yes (pentobarbital sodium)

- Animals fasted: Yes, 16-22h

- How many animals: 5 sex/dose/group

- Parameters checked in table were examined.

- Measurement of thyroid hormone: Yes (T3, T4, TSH)

CLINICAL CHEMISTRY: Yes

- Time schedule for collection of blood: Same as hematology

- Animals fasted: Same as hematology

- How many animals: Same as hematology

- Parameters checked in table were examined.

URINALYSIS: Yes

- Time schedule for collection of urine: on week 6 of administration period (main/recovery group animals) and week 2 of recovery period (recovery group animals).

- Metabolism cages used for collection of urine: Yes

- Animals fasted: no fasting (3h- and 21h-urine)

---

## **Sacrifice and pathology**

### **GROSS NECROPSY**

- Gross necropsy consisted of external and internal examinations including the brain (cerebrum, cerebellum and pons), spinal cord, pituitary, thymus, thyroid gland (including parathyroid), adrenal glands, spleen, heart, esophagus, stomach, liver, pancreas, submandibular gland, duodenum, jejunum, ileum (including Peyer's patches), cecum, colon, rectum, trachea, lung, kidney, bladder, testis, epididymis, prostate, seminal vesicles (including coagulating gland), ovary, uterus (the corners and neck), vagina, eye and Harder gland, mammary gland (right abdomen), femur (including the bone marrow, right), mesenteric lymph nodes, submandibular lymph nodes, skeletal muscle (gastrocnemius), sciatic nerve and gross abnormal site (including the boundary areas between the normal and abnormal sites)

HISTOPATHOLOGY: Organs and tissues (same as gross necropsy)

### **Other examinations**

Organ weight: Brain, pituitary gland, thyroids (including parathyroids), thymus, heart, liver, kidneys, spleen, adrenal gland, thymus, testis, epididymis, prostate (ventral), seminal vesicles (including coagulating gland and secretions), ovary, uterus

### **Statistics**

The data were analyzed for homogeneity of variance by the Bartlett test. If variances were homogeneous, data was analyzed by one-way ANOVA and the Dunnett test, whereas heterogeneous data was analyzed by Kruskal-Wallis test and the Steel test.

For findings two or more grades was observed, data was analyzed by Kruskal-Wallis test and the Steel test. For findings one grade was observed, data was analyzed by a multi-sample chi-square test and a two-sample chi-square test. For the comparison tests with the control group, the significance level was 5%.

---

## **Results and discussion**

---

### **Results of examinations**

#### **Clinical signs**

no effects observed

#### **Mortality**

no mortality observed

#### **Body weight and weight changes**

no effects observed

#### **Food consumption and compound intake (if feeding study)**

effects observed, treatment-related

#### **Food efficiency**

not examined

#### **Water consumption and compound intake (if drinking water study)**

not examined

#### **Ophthalmological findings**

not examined

#### **Haematological findings**

effects observed, treatment-related

---

### **Clinical biochemistry findings**

effects observed, treatment-related

### **Description (incidence and severity)**

including thyroid hormones (T3, T4, and TSH)

### **Urinalysis findings**

effects observed, treatment-related

### **Behaviour (functional findings)**

no effects observed

### **Description (incidence and severity)**

see clinical signs.

### **Organ weight findings including organ / body weight ratios**

effects observed, treatment-related

### **Gross pathological findings**

effects observed, treatment-related

### **Histopathological findings: non-neoplastic**

effects observed, treatment-related

### **Histopathological findings: neoplastic**

not examined

### **Details on results**

#### **FOOD CONSUMPTION**

Low values were observed in females of main group at 600 mg/kg bw/day on 3-5 day of dosing and on 1-3 and 3-5 days of gestation.

#### **HAEMATOLOGY**

In males, at the end of dosing period, low values of red blood cell count, hemoglobin level, and hematocrit were observed at 150 mg/kg bw/day and higher.

At the end of recovery period, low values of red blood cell count, hemoglobin level, and hematocrit, and high value of reticulocyte count were observed at 600 mg/kg bw/day.

In females, at the end of dosing period, low value of reticulocyte count was observed at 600 mg/kg bw/day (main group), and low value of red blood cell count and prolonged activated partial thromboplastin time were observed at 600 mg/kg bw/day (satellite group). No effects were observed at the end of recovery period.

#### **CLINICAL CHEMISTRY**

In males, at 600 mg/kg bw/day: High values of  $\alpha$ 2-globulin fraction, gamma-GTP, total cholesterol, and urea nitrogen, and low value of glucose were observed at the end of dosing period, and high values of gamma-GTP, urea nitrogen, and inorganic phosphorus were observed at the end of recovery period.

In females, at 600 mg/kg bw/day: High values of gamma-GTP and low value of inorganic phosphorus were observed at the end of dosing period (main group), and high values of  $\alpha$ 2-globulin fraction, total cholesterol, and potassium, and low value of total bilirubin and sodium were observed at the end of dosing period (satellite group). Low value of A/G ration and albumin was observed at the end of recovery period.

On the thyroid hormone, high value of T4 was observed in females at the end of the recovery period.

#### **URINALYSIS**

Circular epithelial cells appeared in the urinary sediment of males at 600 mg/kg bw/day.

#### **ORGAN WEIGHTS**

In males, high value of kidney weight at 40 mg/kg bw/day and higher, high value of liver weight at 150 mg/kg bw/day and higher were observed at the end of the dosing period. High value of a kidney weight was observed at 600 mg/kg bw/day at the end of the recovery end.

---

In females, high values of liver weight at 150 mg/kg bw/day and higher, thyroid weight at 600 mg/kg bw/day, and kidney weight at 40 and 600 mg/kg bw/day were observed at the end of the dosing period (main group), and liver, kidney, and thyroid weights at 600 mg/kg bw/day were observed at the end of the dosing period (satellite group). Kidney and thyroid weights at 600 mg/kg bw/day were observed at the end of the recovery period.

GROSS PATHOLOGY: See tables in the full report.

HISTOPATHOLOGY: See tables in the full report.

Main lesions were observed in the kidney and the liver in males, and were observed in the liver and the thyroid in females.

## Effect levels

---

<b>Key result</b> false
<b>Dose descriptor</b> NOAEL
<b>Effect level</b>  40 mg/kg bw/day (actual dose received)
<b>Based on</b> test mat.
<b>Sex</b> male
<b>Basis for effect level</b> other: anemia and increased liver weight
<b>Key result</b> false
<b>Dose descriptor</b> NOAEL
<b>Effect level</b>  40 mg/kg bw/day (actual dose received)
<b>Based on</b> test mat.
<b>Sex</b> female
<b>Basis for effect level</b> other: increased liver weight

## Target system / organ toxicity

---



---

**Key result**

false

**Critical effects observed**

not specified

---

**Any other information on results incl. tables**

Field content is not in a valid XML format and thus ignored!

---

**Applicant's summary and conclusion****Executive summary**

A combined repeated oral dose toxicity study with the reproduction/developmental toxicity screening test was performed according to a Japanese guideline (similar to OECD TG 422). Male and female rats (12 animals/sex/dose) were administered 1-propene, tetramer at 0, 40, 150, and 600 mg/kg bw/day. Males were dosed for 42 days, including a 14-day pre-mating and mating periods. Females were dosed for 40–45 days, including a 14-day pre-mating, mating, and gestation periods and the time until day 4 of lactation. Five out of 12 males with administered doses of 0 and 600 mg/kg bw/day were evaluated as a 14-day recovery group. In addition, 10 females/dose were administered 0 and 600 mg/kg bw/day for 42 days without mating; they were examined after the administration period or after a 14-day recovery period. Regarding hematology parameters, anemia was observed at 150 mg/kg bw/day and higher in males, with decreased red blood cell counts at 600 mg/kg bw/day in females without mating. In the kidney, in males,  $\alpha$ 2u-globulin nephropathy was observed at 40 mg/kg bw/day and higher, with increased kidney weight at 40 mg/kg bw/day and higher and basophilic changes in the tubular epithelium at 150 mg/kg bw/day and higher. Furthermore, necrosis of the tubular epithelium, increased blood urea nitrogen level, and round epithelial cells in urinary sediments were observed in males at 600 mg/kg bw/day. These effects were considered to be caused by  $\alpha$ 2u-globulin accumulation in the kidney as male rat specific disease, and were not relevant in human health. In the liver, in both sexes, increased liver weight was observed at 150 mg/kg bw/day and higher, with centrilobular hepatocytes hypertrophy at 600 mg/kg bw/day. Furthermore, increases in the  $\alpha$ 2-globulin fraction,  $\gamma$ -glutamyl transpeptidase, and total cholesterol levels and a decrease in glucose level were observed at 600 mg/kg bw/day in both sexes. In the thyroid, in females, increased thyroid weight and hypertrophy of follicular cells were observed at 600 mg/kg bw/day, with thyroxin level increasing after the recovery period at this dose. Hematology, kidney, and liver, but not thyroid, changes tended to resolve after the recovery period. On the basis of anemia in males and increased liver weight in both sexes, NOAEL for repeated-dose toxicity was determined to be 40 mg/kg bw/day in male and female rats.

---

## Genetic toxicity in vitro

ENDPOINT\_STUDY\_RECORD: Genetic toxicity in vitro.001

---

**UUID:** IUC5-e1c75adb-a8dd-43ee-864e-bfc1af110861

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:14:20.530+09:00

**Remarks:**

---

## Administrative data

---

### Endpoint

in vitro gene mutation study in bacteria Type of genotoxicity: gene mutation

### Type of information

experimental study

### Adequacy of study

key study

### Robust study summary

false

### Used for classification

false

### Used for SDS

false

### Reliability

1 (reliable without restriction)

### Rationale for reliability incl. deficiencies

other: OECD Test Guideline study under GLP condition

## Data source

---

### Reference

[Reverse Mutation Test of 1-Propene, tetramer on Bacteria. / MHLW, Japan / study report](#)

### Data access

data published

## Materials and methods

---

### Test guideline

#### Qualifier

according to guideline

#### Guideline

JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals

#### Deviations

no

---

**GLP compliance**

yes

**Type of assay**

bacterial reverse mutation assay  
in vitro gene mutation study in bacteria

---

**Test material****Test material information**

1-Propene, tetramer

---

**Method****Species / strain****Species / strain / cell type**

S. typhimurium TA 1535, TA 1537, TA 98 and TA 100  
bacteria

**Species / strain / cell type**

E. coli WP2 uvr A  
bacteria

**Metabolic activation**

with and without

**Metabolic activation system**

rat liver, induced by phenobarbital and 5,6-benzoflavone

**Test concentrations with justification for top dose**

-S9 mix and + S9 mix: 156, 313, 625, 1250, 2500, 5000 µg/plate (all strains)

**Vehicle / solvent**

- Vehicle(s)/solvent(s) used: Acetone

**Controls****Untreated negative controls**

no

**Negative solvent / vehicle controls**

yes

**True negative controls**

other: tests without all strains, and with vehicle, S9 mix or the highest dose

**Positive controls**

yes

**Positive control substance**

other: -S9 mix: 2-(2-Furyl)-3-(5-nitro-2-furyl) acrylamide (AF2:TA 100, TA98 & WP2 uvrA), sodium azide (SA:TA1535) and 9-aminoacridine hydrochloride (9AA:TA1537). +S9 mix: 2-aminoanthracene (2AA:all strains).

**Remarks**

AF2 & 2AA were dissolved with DMSO, and SA & 9AA were dissolved with distilled water.

**Details on test system and experimental conditions**

RANGE-FINDING/SCREENING STUDIES:Concentration: 20-5000 µg/plate

---

Cytotoxic conc.: [-S9mix] No, [+S9mix] No.  
Precipitate: Yes, >1000 µg/plate  
METHOD OF APPLICATION: Preincubation  
DURATION  
- Preincubation period: 20 min at 37 °C  
- Exposure duration: 48 hrs  
NUMBER OF PLATES: 3  
NUMBER OF REPLICATIONS: 2  
DETERMINATION OF CYTOTOXICITY  
- Method: other: growth inhibition

### Evaluation criteria

In any strain(s) tested with or without S9 mix, when the mean number of revertant colonies per plate increased twice more than that of the negative control and when the increase was shown to be dose-related and reproducible, the chemical was judged mutagenic.

### Statistics

No.

## Results and discussion

---

### Test results

**Key result**

false

**Species / strain**

S. typhimurium TA 1535, TA 1537, TA 98 and TA 100  
bacteria

**Metabolic activation**

with and without

**Genotoxicity**

negative

**Cytotoxicity / choice of top concentrations**

no cytotoxicity nor precipitates, but tested up to recommended limit concentrations

**Vehicle controls validity**

valid

**Positive controls validity**

valid

**Key result**

false

**Species / strain**

E. coli WP2 uvr A  
bacteria

**Metabolic activation**

with and without

**Genotoxicity**

negative

---

**Cytotoxicity / choice of top concentrations**

no cytotoxicity nor precipitates, but tested up to recommended limit concentrations

**Vehicle controls validity**

valid

**Positive controls validity**

valid

**Additional information on results**

Contamination with any other bacterias was not found.

**Remarks on result**

other: all strains/cell types tested Migrated from field 'Test system'.

**Any other information on results incl. tables** \_\_\_\_\_

Field content is not in a valid XML format and thus ignored!

**Overall remarks, attachments** \_\_\_\_\_**Attachments****Attached (sanitised) documents for publication**

6842-15-5\_Ames.xlsx / 36.463 KB (application/vnd.openxmlformats-officedocument.spreadsheetml.sheet)

**Applicant's summary and conclusion** \_\_\_\_\_**Conclusions**

Interpretation of results (migrated information):  
negative

**Executive summary**

In a bacterial reverse mutation assay using Salmonella typhimurium TA100, TA1535, TA98, and TA1537 and Escherichia coli WP2uvrA (similar to OECD TG 471), 1-propene, tetramer was negative with or without metabolic activation.

---

**ENDPOINT\_STUDY\_RECORD: Genetic toxicity in vitro.002**

---

**UUID:** IUC5-3058b6ae-b1d0-4a29-8507-f74af19ce5cf

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:14:54.068+09:00

**Remarks:**

---

## Administrative data

---

### Endpoint

in vitro cytogenicity / chromosome aberration study in mammalian cells Type of genotoxicity: chromosome aberration

### Type of information

experimental study

### Adequacy of study

key study

### Robust study summary

false

### Used for classification

false

### Used for SDS

false

### Reliability

1 (reliable without restriction)

### Rationale for reliability incl. deficiencies

other: OECD Test Guideline study under GLP condition

## Data source

---

### Reference

[In Vitro Chromosomal Aberration Test of 1-Propene, tetramer on Cultured Chinese Hamster Cells. / MHLW, Japan / study report](#)

### Data access

data published

## Materials and methods

---

### Test guideline

#### Qualifier

according to guideline

#### Guideline

OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)  
in vitro cytogenicity / chromosome aberration study in mammalian cells

---

---

**Deviations**

no

**Qualifier**

according to guideline

**Guideline**

JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals

**Deviations**

no

**GLP compliance**

yes

**Type of assay**in vitro mammalian chromosome aberration test  
chromosome aberration

---

**Test material****Test material information**[1-Propene, tetramer](#)

---

**Method****Target gene**

Chromosome

**Species / strain****Species / strain / cell type**

other: Chinese hamster lung(CHL/IU) cells

**Metabolic activation**

with and without

**Metabolic activation system**

rat liver, induced by phenobarbital and 5,6-benzoflavone

**Test concentrations with justification for top dose**

-S9 mix (short-term treatment): 0, 53.1, 106, 213, 425 ug/mL

+S9 mix (short-term treatment): 0, 213, 425, 850, 1700 ug/mL

-S9 mix (continuous treatment, 24 h): 0, 53.1, 106, 213, 425 ug/mL

-S9 mix (continuous treatment, 48 h): 0, 53.1, 106, 213, 425 ug/mL

**Vehicle / solvent**

- Vehicle(s)/solvent(s) used:Acetone

**Controls****Untreated negative controls**

no

**Negative solvent / vehicle controls**

yes

**True negative controls**

no

**Positive controls**

yes

**Positive control substance**

cyclophosphamide  
mitomycin C

**Remarks**

mitomycin C (without S9 mix), cyclophosphamide (with S9 mix)

**Details on test system and experimental conditions**

METHOD OF APPLICATION: Exposure duration: [continuous treatment]: 24, 48 hrs [short-term treatment]: 6 hrs + 18 hr

SPINDLE INHIBITOR: Colcemid

NUMBER OF REPLICATIONS: 2

NUMBER OF CELLS EVALUATED: 200 cells / dose

DETERMINATION OF CYTOTOXICITY

- Method: relative total growth

**Evaluation criteria**

For the evaluation of the frequencies of structural aberrations and of polyploidy induced, the following criteria were employed.

Appearance incidence of cells with chromosomal aberrations: Negative (-): < 5%; equivocal ( $\pm$ ): 5-10%; positive (+): > 10%.

Finally, the substance is positive when the incidence is considered to be dose-related and reproducible.

**Statistics**

not used.

## Results and discussion

**Test results****Key result**

false

**Species / strain**

other: Chinese hamster lung (CHL/IU) cells

**Metabolic activation**

with

**Genotoxicity**

negative

**Cytotoxicity / choice of top concentrations**

no cytotoxicity

**Vehicle controls validity**

valid

**Untreated negative controls validity**

not examined

**Positive controls validity**

valid

**Key result**

false



---

**Species / strain**

other: Chinese hamster lung (CHL/IU) cells

**Metabolic activation**

without

**Genotoxicity**

negative

**Cytotoxicity / choice of top concentrations**

cytotoxicity 50% cell growth inhibition: 315.3 ug/mL (short), 336.7 ug/mL (24h continuous) and 219.2 ug/mL (48h continuous)

**Vehicle controls validity**

valid

**Untreated negative controls validity**

not examined

**Positive controls validity**

valid

---

**Any other information on results incl. tables**

Figures and Tables (in English) are available in the following full report of the study.

[http://dra4.nihs.go.jp/mhlw\\_data/home/pdf/PDF6842-15-5f.pdf](http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF6842-15-5f.pdf)

---

**Applicant's summary and conclusion****Executive summary**

An in vitro chromosomal aberration test using CHL/IU cells (OECD TG 473) showed positive.

---

## Toxicity to reproduction

ENDPOINT\_STUDY\_RECORD: Reproductive/developmental toxicity.001

---

**UUID:** IUC5-e522e89f-3b32-4842-a874-9ca34277d649

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:15:45.897+09:00

**Remarks:**

---

## Administrative data

---

### Endpoint

screening for reproductive / developmental toxicity based on test type (migrated information)

### Type of information

experimental study

### Adequacy of study

key study

### Robust study summary

false

### Used for classification

false

### Used for SDS

false

### Reliability

1 (reliable without restriction)

### Rationale for reliability incl. deficiencies

other: The study was conducted in accordance with Test Guidelines and under GLP.

### Cross-reference

#### Reason / purpose for cross-reference

reference to same study

#### Remarks

7.5.1 Repeated dose toxicity: oral.001

---

## Data source

---

### Reference

[Combined repeat dose and reproductive/developmental toxicity screening test of 1-Propene, tetramer b / MHLW, Japan / study report](#)

### Data access

data published

---

## Materials and methods

---

---

## Test guideline

**Qualifier**

equivalent or similar to guideline

**Guideline**

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

**GLP compliance**

yes

---

## Test material

**Test material information**

1-Propene, tetramer

---

## Test animals

**Species**

rat

**Strain**

other: CrI: CD(SD)

**Sex**

male/female

**Details on test animals or test system and environmental conditions****TEST ANIMALS**

- Source: Charles River Laboratories Japan, Inc. Atsugi
- Age at study initiation: 8 weeks
- Weight at study initiation: Males: 264-308 g; Females: 178-225 g
- Housing: bracket-type metallic wire-mesh cages (W 260 × D 380 × H 180 mm)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 12 days

**ENVIRONMENTAL CONDITIONS**

- Temperature (°C): 20-24
- Humidity (%): 41-58
- Air changes: 10-15 times / hr
- Photoperiod: 12 hrs dark / 12 hrs light

---

## Administration / exposure

**Route of administration**

oral: gavage

**Vehicle**

corn oil

**Details on exposure**

PREPARATION OF DOSING SOLUTIONS: Test substance was dissolved in corn oil for injection.

VEHICLE

- 
- Lot/batch no. (if required): VIR7200 produced by Nacalai Tesque, INC.
  - Dosing volume: 5 mL/kg bw
  - Stability (test solutions): At least 9 days
  - Storage condition of test solution: Room temperature

**Details on mating procedure**

- M/F ratio per cage:1:1
- Length of cohabitation:up to 14 days
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0] of pregnancy

**Analytical verification of doses or concentrations**

yes

**Details on analytical verification of doses or concentrations**

Test suspensions at each concentration to be used for males in week 1 and six week of administration were analyzed by the HPLC method at Nisso chemical analysis service Co., Ltd. Results showed that the concentration of the test article in each suspension was 99.7 to 108.2% of the nominal concentration and both values were within the acceptable range (concentration: percentage of the nominal concentration,  $100 \pm 10\%$ ; C.V.: 10% or below)

**Duration of treatment / exposure**

- (P) Males: 42 days including 14 days pre-mating, mating, and thereafter 14 days
- (P) Females: 42–51 days including 14 days pre-mating, mating and gestation periods and the days until day 4 of lactation. 42 days for satellite females (without mating).

**Frequency of treatment**

Once/day, 7 days/week

**Doses / concentrations****Remarks**

Doses / Concentrations:  
0 (vehicle), 40, 150, and 600 mg/kg bw/day  
Basis:  
actual ingested

**No. of animals per sex per dose**

- 12 animals/sex/dose as a main dose group,
- 5\* males and 5 females at 0 and 600 mg/kg bw/day as a satellite group (without mating)
- \* From corresponding main dose groups

**Control animals**

yes, concurrent vehicle

**Examinations**

---

**Parental animals: Observations and examinations**

see 7.5.1 repeated dose toxicity: oral.001

---

### **Oestrous cyclicity (parental animals)**

Vaginal smears were collected from all females in the main groups and microscopically examined every day from the day after the start of administration until the day copulation was confirmed.

During the pre-mating administration period, vaginal smear pictures were classified as proestrus, estrus, metestrus or diestrus and examined for the frequency of estrus and interval between estruses (estrous cycle). During the mating period, vaginal smears were examined for the presence of sperm.

### **Sperm parameters (parental animals)**

Parameters examined in P male parental generations: testes weight, epididymides weight

### **Litter observations**

PARAMETERS EXAMINED: The following parameters were examined in F1 offspring:

Number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, and weight gain.

GROSS EXAMINATION OF DEAD PUPS: Yes, for external and internal abnormalities.

### **Postmortem examinations (parental animals)**

#### **SACRIFICE**

- Male animals: Rats were euthanized by exsanguination under ether anesthesia on the day after the last administration.

- Maternal animals: Rats were euthanized by exsanguination under ether anesthesia on day 4 of lactation.

#### **GROSS NECROPSY**

- Gross necropsy consisted of external and internal examinations including the brain (cerebrum, cerebellum and pons), spinal cord, pituitary, thymus, thyroid gland (including parathyroid), adrenal glands, spleen, heart, esophagus, stomach, liver, pancreas, submandibular gland, duodenum, jejunum, ileum (including Peyer's patches), cecum, colon, rectum, trachea, lung, kidney, bladder, testis, epididymis, prostate, seminal vesicles (including coagulating gland), ovary, uterus (the corners and neck), vagina, eye and Harder gland, mammary gland (right abdomen), femur (including the bone marrow, right), mesenteric lymph nodes, submandibular lymph nodes, skeletal muscle (gastrocnemius), sciatic nerve and gross abnormal site (including the boundary areas between the normal and abnormal sites)

ORGAN WEIGHT: Brain, pituitary gland, thyroids (including parathyroids), thymus, heart, liver, kidneys, spleen, adrenal gland, thymus, testis, epididymis, prostate (ventral), seminal vesicles (including coagulating gland and secretions), ovary, uterus

HISTOPATHOLOGY: See "Gross necropsy."

### **Postmortem examinations (offspring)**

#### **SACRIFICE**

- The F1 pups were sacrificed at PND 4 by exsanguination under ether anesthesia.

#### **GROSS NECROPSY**

- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.

### **Statistics**

The data were analyzed for homogeneity of variance by the Bartlett test. If variances were homogeneous, data was analyzed by one-way ANOVA and the Dunnett test, whereas heterogeneous data was analyzed by Kruskal-Wallis test and the Steel test.

For findings two or more grades was observed, data was analyzed by Kruskal-Wallis test and the Steel test. For findings one grade was observed, data was analyzed by a multi-sample chi-square test and a two-sample chi-square test. For the comparison tests with the control group, the significance level was 5%.

---

### **Reproductive indices**

Each parameter was determined by the following equations:

Duration of gestation (days) = day 0 of lactation – day 0 of gestation

Abnormal estrous cycle = (No. of female with abnormal estrous cycle / No. of females examined) × 100

Copulation index (males or females, %) = (No. of copulated males or females/No. of co-housed males or females) × 100

Fertility index (%) = (No. of pregnant females/No. of copulated females) × 100

Gestation index (%) = (No. of females delivered liveborn pups/No. of pregnant females) × 100

Nursing index (%) = (No. of females nursing live pups on lactation day 4/No. of females with live pups delivery) × 100

Implantation index (per litter, %) = (No. of implantation sites/No. of corpora lutea) × 100

Delivery index (per litter, %) = (No. of pups born/No. of implantation sites) × 100

Sex ratio on Lactation day 0 = (No. of male pups born / No. of pups born) and (No. of live male pups / No. of live pups)

Sex ratio on Lactation day 4 = No. of live male pups/No. of live pups

Live birth index (%) = (No. of liveborn pups/Total No. of pups born) × 100

### **Offspring viability indices**

Viability index (%) = (No. of surviving pus on day 4 after birth/No. of liveborn pups on day 0 after birth) × 100

---

## **Results and discussion**

### **Results: P0 (first parental generation)**

#### **General toxicity (P0)**

**Organ weight findings including organ / body weight ratios**

no effects observed

**Description (incidence and severity)**

(on reproductive organs)

**Gross pathological findings**

no effects observed

**Description (incidence and severity)**

(on reproductive organs)

**Histopathological findings: non-neoplastic**

no effects observed

**Description (incidence and severity)**

(on reproductive organs)

#### **Reproductive function / performance (P0)**

**Reproductive function: oestrous cycle**

no effects observed

**Reproductive performance**

no effects observed

#### **Effect levels (P0)**

---

---

**Key result**

false

**Dose descriptor**

NOAEL

**Effect level**

600

mg/kg bw/day (actual dose received)

**Sex**

male/female

**Basis for effect level**

other: No effects on reproduction

---

**Results: F1 generation**

---

**General toxicity (F1)****Clinical signs**

no effects observed

**Mortality / viability**

no mortality observed

**Body weight and weight changes**

no effects observed

**Sexual maturation**

not examined

**Organ weight findings including organ / body weight ratios**

not examined

**Gross pathological findings**

no effects observed

**Histopathological findings**

no effects observed

---

**Effect levels (F1)****Key result**

false

**Dose descriptor**

NOAEL

**Generation**

F1

**Effect level**

600

mg/kg bw/day (actual dose received)

---

**Sex**

male/female

**Basis for effect level**

other: No effects on development

---

**Overall reproductive toxicity****Key result**

false

**Reproductive effects observed**

not specified

---

**Any other information on results incl. tables**

Field content is not in a valid XML format and thus ignored!

---

**Applicant's summary and conclusion****Conclusions**

NOAEL for the rat reproductive/developmental toxicity of 1-propene, tetramer was determined to be 600 mg/kg bw/day, the highest dose tested.

**Executive summary**

In the combined repeated oral dose toxicity study (0, 40, 150, and 600 mg/kg bw/day) with the reproduction/developmental toxicity screening test (OECD TG 422), no effects of this substance on reproductive and developmental parameters were observed at 600 mg/kg bw/day. NOAEL for the rat reproductive/developmental toxicity of 1-propene, tetramer was determined to be 600 mg/kg bw/day, the highest dose tested.



---

## DOMAIN

### Substance

**SUBSTANCE:** 1-propene, tetramer

---

**UUID:** IUC5-e0ca2a88-57ae-44ba-bb7f-0f74fba1efe5

**Dossier UUID:**

**Author:**

**Date:** 2022-12-16T16:15:56.420+09:00

**Remarks:**

---

#### Substance name

1-propene, tetramer

#### Legal entity

[National Institute of Health Sciences / Kawasaki / Japan](#)

## Identification of substance

---

#### Reference substance

[1-propene, tetramer / 6842-15-5](#)

**EC number**

**EC name**

**CAS number**

**CAS name**

6842-15-5

**IUPAC name**

## Role in the supply chain

---

#### Manufacturer

false

#### Importer

false

#### Only representative

false

#### Downstream user

false

---

# References

## Reference Substances

### REFERENCE\_SUBSTANCE: 1-propene, tetramer

---

**UUID:** IUC5-67a7f2be-af23-4a38-8ea7-67a5ffccffba

**Dossier UUID:**

**Author:**

**Date:** 2017-10-30T11:27:04.000+09:00

**Remarks:**

---

**Reference substance name**

1-propene, tetramer

## Inventory

---


**CAS number**

6842-15-5

## Molecular and structural information

---

**Structural formula**



---

# Test Materials

## TEST\_MATERIAL\_INFORMATION: 1-Propene, tetramer

---

**UUID:** e334fdc6-f78b-3025-a4d2-f4c305496a6f

**Dossier UUID:**

**Author:**

**Date:** 2022-12-15T10:52:15.792+09:00

**Remarks:**

---

### Name

1-Propene, tetramer

## Composition

---

### Composition

#### Type

Constituent

#### Reference substance

1-propene, tetramer / 6842-15-5

**EC number**

**EC name**

**CAS number**

**CAS name**

6842-15-5

**IUPAC name**

## Other characteristics

---

### Details on test material

Name of test material (as cited in study report): 1-Propene, tetramer

- Analytical purity: 99.9%

- Lot/batch No.: MZ5G05-2

- Storage condition of test material: at a cold place (temperature 2~6°C) in a light resistant container

- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

---

## TEST\_MATERIAL\_INFORMATION: 1-Propene, tetramer

---

**UUID:** a7b2c6cb-5090-36bb-abb7-b59599e70713

**Dossier UUID:**

**Author:**

**Date:** 2022-12-15T10:40:41.973+09:00

**Remarks:**

---

### Name

1-Propene, tetramer

## Composition

---

### Composition

**Type**

Constituent

**Reference substance**

1-propene, tetramer / 6842-15-5

**EC number**

**EC name**

**CAS number**

**CAS name**

6842-15-5

**IUPAC name**

## Other characteristics

---

### Details on test material

Name of test material (as cited in study report): Propylenetetramer

- Analytical purity: 99.9%

- Lot/batch No.: C6UE654

- Storage condition of test material: at a cold place (temperature 2~10 °C) in a light resistant container

- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

---

## TEST\_MATERIAL\_INFORMATION: 1-Propene, tetramer

---

**UUID:** e1d877e3-561a-33ec-8363-d285fa00151a

**Dossier UUID:**

**Author:**

**Date:** 2022-12-15T10:46:32.444+09:00

**Remarks:**

---

### Name

1-Propene, tetramer

## Composition

---

### Composition

**Type**

Constituent

**Reference substance**

1-propene, tetramer / 6842-15-5

**EC number**

**EC name**

**CAS number**

**CAS name**

6842-15-5

**IUPAC name**

## Other characteristics

---

### Details on test material

- Name of test material (as cited in study report): 1-Propene, tetramer
- Analytical purity: 71.2% for (C<sub>3</sub>H<sub>6</sub>)<sub>4</sub>
- Supplier: Nippon Oil Corporation
- Lot/batch No.: MZ5A01
- Storage condition of test material: under room temperature, closed container

---

## TEST\_MATERIAL\_INFORMATION: 1-Propene, tetramer

---

**UUID:** d25d1671-4d65-3bad-8e32-fbb280dac1a4

**Dossier UUID:**

**Author:**

**Date:** 2022-12-15T10:44:40.336+09:00

**Remarks:**

---

### Name

1-Propene, tetramer

## Composition

---

### Composition

**Type**

Constituent

**Reference substance**

1-propene, tetramer / 6842-15-5

**EC number**

**EC name**

**CAS number**

**CAS name**

6842-15-5

**IUPAC name**

## Other characteristics

---

### Details on test material

- Name of test material (as cited in study report): 1-Propene, tetramer
- Purity: 99.9%
- Lot/batch No.: MZ5G05-2
- Storage condition of test material: Refrigeration
- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

---

## Literatures

### LITERATURE: Combined repeat dose and reproductive/ developmental toxicity screening test of 1-Propene, tetramer by oral administration in rats

---

**UUID:** 660d1cf9-7876-3bf6-9119-c6d011cadd7

**Dossier UUID:**

**Author:**

**Date:** 2017-02-15T15:56:31.000+09:00

**Remarks:**

---

## General information

---

### Reference Type

study report

### Title

Combined repeat dose and reproductive/developmental toxicity screening test of 1-Propene, tetramer by oral administration in rats

### Author

MHLW, Japan

### Year

2013

### Bibliographic source

available in the web of Japan Existing Chemical Data Base (JECDB) at [http://dra4.nihs.go.jp/mhlw\\_data/jsp/SearchPageENG.jsp](http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp)

### Testing facility

Safety Research Institute for Chemical Compounds Co., Ltd.

---

# LITERATURE: In Vitro Chromosomal Aberration Test of 1-Propene, tetramer on Cultured Chinese Hamster Cells.

---

**UUID:** 17074494-e98d-3b6c-b658-4c47fbe425cd

**Dossier UUID:**

**Author:**

**Date:** 2017-02-15T15:59:26.000+09:00

**Remarks:**

---

## General information

---

### Reference Type

study report

### Title

In Vitro Chromosomal Aberration Test of 1-Propene, tetramer on Cultured Chinese Hamster Cells.

### Author

MHLW, Japan

### Year

2006

### Bibliographic source

Japan Existing Chemical Data Base (JECDB)

### Testing facility

BoZo Research Center



---

## LITERATURE: Reverse Mutation Test of 1-Propene, tetramer on Bacteria.

---

**UUID:** 9cab12b7-5381-3ef6-9a60-ca82a090a84a

**Dossier UUID:**

**Author:**

**Date:** 2017-02-15T15:58:12.000+09:00

**Remarks:**

---

### General information

---

**Reference Type**

study report

**Title**

Reverse Mutation Test of 1-Propene, tetramer on Bacteria.

**Author**

MHLW, Japan

**Year**

2006

**Bibliographic source**

Japan Existing Chemical Data Base (JECDB)

**Testing facility**

Research Institute for Animal Science in Biochemistry & Toxicology (RIAS)

---

# LITERATURE: Single Dose Oral Toxicity Test of 1-Propene, tetramer in Rats

---

**UUID:** 5da23c5a-577c-376b-9ef5-ad3683ba9b5a

**Dossier UUID:**

**Author:**

**Date:** 2017-02-15T15:52:21.000+09:00

**Remarks:**

---

## General information

---

### Reference Type

study report

### Title

Single Dose Oral Toxicity Test of 1-Propene, tetramer in Rats

### Author

MHLW, Japan

### Year

2006

### Bibliographic source

available in the web of Japan Existing Chemical Data Base (JECDB) at [http://dra4.nihs.go.jp/mhlw\\_data/jsp/SearchPageENG.jsp](http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp)

### Testing facility

Research Institute for Animal Science in Biochemistry and Toxicology.

---

# Legal Entities

## LEGAL\_ENTITY: National Institute of Health Sciences

---

**UUID:** IUC4-b036ff75-0f3c-323b-b200-ed5f46cf5101

**Dossier UUID:**

**Author:**

**Date:** 2022-11-07T15:49:29.000+09:00

**Remarks:**

---

### General information

---

**Legal entity name**

National Institute of Health Sciences

**Remarks**

Disclaimer: The contents in this document were created based on the MHLW (Ministry of Health, Labour and Welfare) peer reviewed study reports (in Japanese) in JECDB (Japan Existing Chemical Database) at [http://dra4.nihs.go.jp/mhlw\\_data/jsp/SearchPageENG.jsp](http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp). Authorship is in the Division of Risk Assessment, the National Institute of Health Sciences, and the contents do not reflect any official MHLW opinions or any other regulatory policies.

### Address

---

**Address 1**

Tonomachi 3-25-26

**Address 2**

Kawasaki-ku

**Postal code**

210-9501

**Town**

Kawasaki

**Region / State**

Kanagawa

**Country**

Japan

JP

### Identifiers

---

**Other IT system identifiers**

<b>IT system</b>
LEO
<b>ID</b>
10767
<b>IT system</b>
IUCLID4

---

**ID**

16558402024DIV750